SE0201977D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
SE0201977D0
SE0201977D0 SE0201977A SE0201977A SE0201977D0 SE 0201977 D0 SE0201977 D0 SE 0201977D0 SE 0201977 A SE0201977 A SE 0201977A SE 0201977 A SE0201977 A SE 0201977A SE 0201977 D0 SE0201977 D0 SE 0201977D0
Authority
SE
Sweden
Prior art keywords
novel compounds
compounds
diseases associated
inhibitors
cathepsin
Prior art date
Application number
SE0201977A
Other languages
English (en)
Inventor
Andrew Bailey
Anil Patel
Garry Pairaudeau
Stephen Thom
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0201977A priority Critical patent/SE0201977D0/sv
Publication of SE0201977D0 publication Critical patent/SE0201977D0/sv
Priority to EP03761003A priority patent/EP1532124B1/en
Priority to DK03761003T priority patent/DK1532124T3/da
Priority to PCT/SE2003/001080 priority patent/WO2004000825A1/en
Priority to US10/518,818 priority patent/US20050245522A1/en
Priority to PT03761003T priority patent/PT1532124E/pt
Priority to DE60306934T priority patent/DE60306934T2/de
Priority to JP2004515330A priority patent/JP2005533805A/ja
Priority to AU2003243097A priority patent/AU2003243097A1/en
Priority to ES03761003T priority patent/ES2268423T3/es
Priority to AT03761003T priority patent/ATE333451T1/de
Priority to SI200330491T priority patent/SI1532124T1/sl
Priority to CY20061101476T priority patent/CY1107342T1/el
Priority to US12/132,080 priority patent/US20080234274A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C07D211/66—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrane Compounds (AREA)
SE0201977A 2002-06-24 2002-06-24 Novel compounds SE0201977D0 (sv)

Priority Applications (14)

Application Number Priority Date Filing Date Title
SE0201977A SE0201977D0 (sv) 2002-06-24 2002-06-24 Novel compounds
SI200330491T SI1532124T1 (sl) 2002-06-24 2003-06-23 Uporaba nitrilnih derivatov kot zdravila
DE60306934T DE60306934T2 (de) 2002-06-24 2003-06-23 Verwendung von Nitrilenverbindungen als Arzneimittel
DK03761003T DK1532124T3 (da) 2002-06-24 2003-06-23 Anvendelse af nitriderivater som medikament
PCT/SE2003/001080 WO2004000825A1 (en) 2002-06-24 2003-06-23 Novel compounds
US10/518,818 US20050245522A1 (en) 2002-06-24 2003-06-23 Novel compounds
PT03761003T PT1532124E (pt) 2002-06-24 2003-06-23 Utilização de derivados de nitrilo como medicamento
EP03761003A EP1532124B1 (en) 2002-06-24 2003-06-23 Use of nitrile derivatives as medicament.
JP2004515330A JP2005533805A (ja) 2002-06-24 2003-06-23 新規化合物
AU2003243097A AU2003243097A1 (en) 2002-06-24 2003-06-23 Novel compounds
ES03761003T ES2268423T3 (es) 2002-06-24 2003-06-23 Uso de derivados de nitrilo como medicamento.
AT03761003T ATE333451T1 (de) 2002-06-24 2003-06-23 Verwendung von nitrilenverbindungen als arztneimittel
CY20061101476T CY1107342T1 (el) 2002-06-24 2006-10-13 Χρηση παραγωγων νιτριλιου ως φαρμακο
US12/132,080 US20080234274A1 (en) 2002-06-24 2008-06-03 Novel Compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0201977A SE0201977D0 (sv) 2002-06-24 2002-06-24 Novel compounds

Publications (1)

Publication Number Publication Date
SE0201977D0 true SE0201977D0 (sv) 2002-06-24

Family

ID=20288335

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0201977A SE0201977D0 (sv) 2002-06-24 2002-06-24 Novel compounds

Country Status (12)

Country Link
US (2) US20050245522A1 (sv)
EP (1) EP1532124B1 (sv)
JP (1) JP2005533805A (sv)
AT (1) ATE333451T1 (sv)
AU (1) AU2003243097A1 (sv)
CY (1) CY1107342T1 (sv)
DE (1) DE60306934T2 (sv)
DK (1) DK1532124T3 (sv)
ES (1) ES2268423T3 (sv)
PT (1) PT1532124E (sv)
SE (1) SE0201977D0 (sv)
WO (1) WO2004000825A1 (sv)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0201977D0 (sv) * 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
CA2529984C (en) 2003-06-26 2012-09-25 Isa Odidi Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors
EP1644326B1 (en) * 2003-06-30 2016-11-02 Merck Canada Inc. Cathepsin cysteine protease inhibitors
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
CA3063263C (en) 2006-02-11 2024-01-16 Genetronics, Inc. Device and method for single-needle in vivo electroporation
JP5457830B2 (ja) 2006-04-03 2014-04-02 オディディ，イサ オルガノゾル被膜を含む制御放出送達デバイス
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US20080269241A1 (en) * 2007-02-15 2008-10-30 Darin Allen Bicyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s
US20090099157A1 (en) * 2007-02-15 2009-04-16 Ameriks Michael K Tetrahydro-pyrazolo-pyridine thioether modulators of cathepsin s
US20090118274A1 (en) * 2007-02-15 2009-05-07 Darin Allen Monocyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s
US20080200454A1 (en) * 2007-02-15 2008-08-21 Ameriks Michael K Carbon-linked tetrahydro-pyrazolo-pyridine modulators of cathepsin s
US20080207683A1 (en) * 2007-02-15 2008-08-28 Darin Allen Biaryl-substituted tetrahydro-pyrazolo-pyridine modulators of cathepsin s
WO2009001128A1 (en) * 2007-06-26 2008-12-31 Astrazeneca Ab 1,2-cycl0hexane dicarboxamides as cathepsin inhibitors
AU2008269513B2 (en) * 2007-06-26 2011-06-16 Astrazeneca Ab 1-cyanocyclopropyl-derivatives as cathepsin K inhibitors
WO2009001127A1 (en) * 2007-06-26 2008-12-31 Astrazeneca Ab Cyanocyclopropylcarboxamides as cathepsin inhibitors
US7893099B2 (en) * 2009-06-11 2011-02-22 Hoffman-La Roche Inc. Cyclopentane derivatives
EP2450755B1 (fr) * 2010-11-04 2015-01-21 Nivarox-FAR S.A. Echappement synchrone pour mécanisme d'horlogerie
US20220193048A1 (en) 2019-04-05 2022-06-23 Universite De Bretagne Occidentale Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1178958B1 (en) * 1999-03-15 2004-02-18 Axys Pharmaceuticals, Inc. N-cyanomethyl amides as protease inhibitors
MXPA02001014A (es) * 1999-07-30 2002-08-12 Boehringer Ingelheim Pharma Nuevos compuestos derivados de succinato utiles como inhibidores de cisteina-proteasa.
US20010041700A1 (en) * 1999-07-30 2001-11-15 Younes Bekkali Novel succinate derivative compounds useful as cysteine protease inhibitors
SE0201977D0 (sv) * 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
CY1107342T1 (el) 2012-12-19
EP1532124A1 (en) 2005-05-25
AU2003243097A1 (en) 2004-01-06
PT1532124E (pt) 2006-11-30
EP1532124B1 (en) 2006-07-19
JP2005533805A (ja) 2005-11-10
WO2004000825A1 (en) 2003-12-31
DE60306934T2 (de) 2007-02-15
ATE333451T1 (de) 2006-08-15
DE60306934D1 (de) 2006-08-31
DK1532124T3 (da) 2006-10-30
US20080234274A1 (en) 2008-09-25
US20050245522A1 (en) 2005-11-03
ES2268423T3 (es) 2007-03-16

Similar Documents

Publication Publication Date Title
SE0201980D0 (sv) Novel compounds
CY1107342T1 (el) Χρηση παραγωγων νιτριλιου ως φαρμακο
SE0201976D0 (sv) Novel compounds
ATE387197T1 (de) Cyanoalkylamino-derivate als protease-hemmer
NO20061627L (no) Haloalkyl inneholdende forbindelser som cysteinproteaseinhibitorer
YU17402A (sh) Nova spiroheterociklična jedinjenja upotrebljiva kao reverzibilni inhibitori cisteinskih proteaza
ATE483692T1 (de) Als beta-sekretase (bace)-hemmer nützliche 2- amino-chinazolinderivate
ATE482936T1 (de) Als b-sekretase (bace)-hemmer nützliche 2-amino- chinazolinderivate
TR200002940T2 (tr) Parazitlerin sebep olduğu hastalıkların papain süperfamilyasından sistein proteazların inhibisyonu yoluyla tedavisi
TW200700057A (en) Alpha ketoamide compounds as cysteine protease inhibitors
WO2003029200A3 (en) Compounds useful as reversible inhibitors of cysteine proteases
WO2005074904A3 (en) Silinane compounds as cysteine protease inhibitors
SE0203712D0 (sv) Novel compounds
DK1539724T3 (da) Aminobenzothiazolforbindelser med NOS-inhiberende aktivitet
TW200509919A (en) Cathepsin S inhibitors
MX2007011739A (es) Compuestos que contienen sulfonilo como inhibidores de cisteina proteasa.
WO2005063742A3 (en) Amidino compounds as cysteine protease inhibitors
MX2009003563A (es) Compuestos que contienen di-fluoro como inhibidores de proteasa de cisteina.
WO2002023784A3 (en) Cysteine protease inhibitors
CR6462A (es) Compuestos y composiciones como inhibidores de proteaso